Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Essat, M., Tappenden, P., Ren, S. et al. (5 more authors) (2015) Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics. ISSN 1170-7690

Abstract

Metadata

Authors/Creators:
  • Essat, M.
  • Tappenden, P.
  • Ren, S.
  • Bessey, A.
  • Archer, R.
  • Wong, R.
  • Lobo, A.
  • Hoque, S.
Copyright, Publisher and Additional Information: © Crown Copyright 2015, published by Springer Verlag. This is an author produced version of a paper subsequently published in PharmacoEconomics. Uploaded in accordance with the publisher's self-archiving policy.
Dates:
  • Published: 17 October 2015
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Health and Related Research (Sheffield)
Depositing User: Symplectic Sheffield
Date Deposited: 29 Oct 2015 14:50
Last Modified: 26 Oct 2016 11:38
Published Version: http://dx.doi.org/10.1007/s40273-015-0334-3
Status: Published
Publisher: Springer Verlag
Refereed: Yes
Identification Number: https://doi.org/10.1007/s40273-015-0334-3
Related URLs:

Download

Share / Export

Statistics